Table 2.
Intervention characteristics of the included trials.
| Study | Dosage | Duration | Outcome | |
|---|---|---|---|---|
| Control group | Trial group | |||
| Peifeng, 2015 [15] | NF (2 times/d, 30 mg/times) | TGD (52.5 g/times, 2∼3 times/d) + NF (2 times/d, 30 mg/times) | 1 month | Ae |
| Xiaofei et al., 2016 [16] | NF (1 times/d, 30 mg/times) | TGD (51.2 g/times, 2∼3 times/d) + NF (1 times/d, 30 mg/times) | 2 weeks | Ae TCMS |
| Tao, 2016 [17] | NF (2 times/d, 10 mg/times) | TGD (48.4 g/times, 2∼3 times/d) + NF (2 times/d, 10 mg/times) | 8 weeks | BP Scr BUN |
| Yingke, 2014 [18] | NFS (2 times/d, 10 mg/times) | TGD (52 g/times, 2∼3 times/d) + NFS (2 times/d, 10 mg/times) | 2 weeks | Ae TCMS |
| Jinbo, 2015 [19] | NFS (2 times/d, 10 mg/times) | TGD (57 g/times, 2 times/d) + NFS (2 times/d, 10 mg/times) | 2 weeks | Ae |
| Fan and Lili, 2015 [20] | NFS (1 times/d, 5 mg/times) | TGD (87.5 g/times 2 times/d) + NFS (1 times/d, 5 mg/times) | 3 months | Ae |
| Pan, 2019 [21] | NFS (1 times/d, 20 mg/times) | TGD (90 g/times, 2 times/d) + NFS (1 times/d, 20 mg/times) | 2 weeks | BP |
| Xiaofang, 2016 [22] | NFS (2 times/d, 20 mg/times) | TGD (125 g/d) + NFS (2 times/d, 20 mg/times) | NR | Ae BP Ar |
| Fu, 2018 [23] | NFS (2 times/d, 20 mg/times) | TGD (57 g/times, 2 times/d) + NFS (2 times/d, 20 mg/times) | 6 months | Ae BP Ar |
| Caihong, 2017 [24] | NFS (1 times/d, 30 mg/times) | TGD (79 g/times, 2 times/d) + NFS (1 times/d, 30 mg/times) | NR | Ae BP |
| Dai, 2019 [25] | NF (1 times/d, 20 mg/times) | TGD (NR) + NF (1 times/d, 20 mg/times) | 2 weeks | Ae BP Ar |
| Yugao, 2017 [26] | NFS (2 times/d, 10 mg/times) | TGD (52 g/times, 3 times/d) + NFS (2 times/d, 10 mg/times) | 8 weeks | Ae BP life quality |
| Peng et al., 2016 [27] | NFC (1 times/d, 30 mg/times, after half a month, 2 times/d, 30 mg/times) | TGD (46.7 g/times 2 times/d) + NFC (1 times/d, 30 mg/times, after half a month, 2 times/d, 30 mg/times) | 2 months | Ae BP |
| Yingjun, 2015 [28] | NFS (2 times/d, 10 mg/times) | TGD (68.8 g/times, 3 times/d) + NFS (2 times/d, 10 mg/times) | NR | Ae BP |
Notes: NF: nifedipine; NFS: nifedipine sustained-release tablets; NFC: nifedipine controlled-release tablets; NR: no report; Ae: antihypertensive effect; TCMS: traditional Chinese medicine symptoms; BP: blood pressure; Scr: serum creatinine; BUN: blood urea nitrogen; Ar: adverse reactions. TGD was taken as a decoction when taken by patients.